{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:52:55Z","timestamp":1792698775404,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["F202322"],"award-info":[{"award-number":["F202322"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002703","name":"Jiangsu University","doi-asserted-by":"publisher","award":["JDYY2023038"],"award-info":[{"award-number":["JDYY2023038"]}],"id":[{"id":"10.13039\/501100002703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002703","name":"Jiangsu University","doi-asserted-by":"publisher","award":["JC-2023-004"],"award-info":[{"award-number":["JC-2023-004"]}],"id":[{"id":"10.13039\/501100002703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016105","name":"Project on Maternal and Child Health Talents of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013094","name":"Science and Technology Planning Social Development Project of Zhenjiang City","doi-asserted-by":"publisher","award":["SH2024091"],"award-info":[{"award-number":["SH2024091"]}],"id":[{"id":"10.13039\/501100013094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189539","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:58:54Z","timestamp":1769011134000},"page":"189539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The interplay between cytokines and immune checkpoints in breast cancer therapy"],"prefix":"10.1016","volume":"1881","author":[{"given":"Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakari","family":"Shaibu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer: biomarker evaluation of the IMpassion130 study","volume":"113","author":"Emens","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189539_bb0015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189539_bb0020","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189539_bb0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0045","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signaling in immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor Signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0065","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189539_bb0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","article-title":"Spatiotemporal immune landscape of colorectal Cancer liver metastasis at single-cell level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189539_bb0085","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","article-title":"Spatial omics and multiplexed imaging to explore cancer biology","volume":"18","author":"Lewis","year":"2021","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.bbcan.2026.189539_bb0095","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1200\/JCO.2009.27.2419","article-title":"Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers","volume":"28","author":"Bianchini","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104120","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges","volume":"10","author":"Schlam","year":"2025","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189539_bb0105","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189539_bb0110","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10257","key":"10.1016\/j.bbcan.2026.189539_bb0120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2016.10.010","article-title":"Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer","volume":"49","author":"Luen","year":"2017","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189539_bb0130","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast Cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"issue":"7791","key":"10.1016\/j.bbcan.2026.189539_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189539_bb0140","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/annonc\/mdx557","article-title":"LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1\/PD-L1+ tumors","volume":"28","author":"Burugu","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0145","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189539_bb0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189539_bb0160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bbcan.2026.189539_bb0165","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189539_bb0170","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of Sabatolimab, an anti-TIM-3 antibody, alone and in combination with Spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189539_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051033","article-title":"Regulation of T(H)17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis","volume":"18","author":"Brockmann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7559","key":"10.1016\/j.bbcan.2026.189539_bb0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189539_bb0190","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s43018-023-00623-x","article-title":"A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer","volume":"4","author":"Bobisse","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189539_bb0195","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1078-0432.CCR-12-2214","article-title":"Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination","volume":"19","author":"Melero","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid Tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189539_bb0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Park","year":"2010","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0215","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid Tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189539_bb0220","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0225","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0230","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","article-title":"Deep profiling of mouse splenic architecture with CODEX multiplexed imaging","volume":"174","author":"Goltsev","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10549-006-9328-3","article-title":"Significance of interleukin-6 (IL-6) in breast cancer (review)","volume":"102","author":"Kn\u00fcpfer","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"issue":"7764","key":"10.1016\/j.bbcan.2026.189539_bb0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0250","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon Signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0255","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0260","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0270","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189539_bb0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fimmu.2014.00327","article-title":"NOD-like receptors: master regulators of inflammation and Cancer","volume":"5","author":"Saxena","year":"2014","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0280","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PloS One"},{"issue":"424","key":"10.1016\/j.bbcan.2026.189539_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0305","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0310","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189539_bb0315","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0320","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41565-019-0485-z","article-title":"Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy","volume":"14","author":"Zhou","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189539_bb0325","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 Signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010294","article-title":"T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy","volume":"13","author":"Bear","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0335","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","article-title":"TGF-\u03b2 inhibition enhances chemotherapy action against triple-negative breast cancer","volume":"123","author":"Bhola","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0340","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189539_bb0345","doi-asserted-by":"crossref","first-page":"v853","DOI":"10.1093\/annonc\/mdz394.003","article-title":"LBA8_PR - KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)","volume":"30","author":"Schmid","year":"2019","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189539_bb0350","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10265","key":"10.1016\/j.bbcan.2026.189539_bb0355","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0360","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0365","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189539_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104577","article-title":"Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions","volume":"206","author":"Caltavituro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"36","key":"10.1016\/j.bbcan.2026.189539_bb0375","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"Daud","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0380","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in Cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189539_bb0385","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189539_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123094","article-title":"A mitochondria-interfering nanocomplex cooperates with photodynamic therapy to boost antitumor immunity","volume":"317","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"issue":"7291","key":"10.1016\/j.bbcan.2026.189539_bb0395","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0400","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0405","first-page":"450","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0410","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to Cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0415","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nbt.2621","article-title":"Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies","volume":"31","author":"Spiess","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"6379","key":"10.1016\/j.bbcan.2026.189539_bb0420","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189539_bb0425","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10(+)GPR77(+) Cancer-associated fibroblasts promote Cancer formation and chemoresistance by sustaining Cancer stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0430","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat. Commun."},{"issue":"7637","key":"10.1016\/j.bbcan.2026.189539_bb0435","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0440","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"issue":"50","key":"10.1016\/j.bbcan.2026.189539_bb0445","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0450","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189539_bb0455","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0460","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast Cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.bbcan.2026.189539_bb0465","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","article-title":"Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy","volume":"1","author":"Valpione","year":"2020","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189539_bb0475","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189539_bb0480","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat. Med."},{"issue":"7652","key":"10.1016\/j.bbcan.2026.189539_bb0485","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0490","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.celrep.2018.03.086","article-title":"Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images","volume":"23","author":"Saltz","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189539_bb0495","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0500","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189539_bb0505","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nmat4290","article-title":"Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates","volume":"14","author":"Veiseh","year":"2015","journal-title":"Nat. Mater."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:35:24Z","timestamp":1782030924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000119"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189539","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interplay between cytokines and immune checkpoints in breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189539"}}